Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 4.8% – Here’s Why

Maze Therapeutics, Inc. (NASDAQ:MAZE) shares rose 4.8% on Tuesday . The company traded as high as $12.13 and last traded at $12.04. Approximately 31,787 shares changed hands during mid-day trading, a decline of 87% from the average daily volume of 244,637 shares. The stock had previously closed at $11.49.

Wall Street Analyst Weigh In

MAZE has been the topic of a number of research reports. Leerink Partners started coverage on shares of Maze Therapeutics in a research note on Tuesday, February 25th. They issued an “outperform” rating and a $28.00 target price on the stock. Guggenheim started coverage on shares of Maze Therapeutics in a research report on Tuesday, February 25th. They set a “buy” rating and a $19.00 price target on the stock. JPMorgan Chase & Co. began coverage on shares of Maze Therapeutics in a research report on Tuesday, February 25th. They set an “overweight” rating and a $30.00 price target on the stock. TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a report on Tuesday, February 25th. Finally, Leerink Partnrs upgraded shares of Maze Therapeutics to a “strong-buy” rating in a report on Tuesday, February 25th. Three investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $25.67.

Maze Therapeutics Stock Performance

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.